^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HOXB13 (Homeobox B13)

    i
    Other names: HOXB13, Homeobox B13, Homeobox Protein Hox-B13
    Associations

    News

    Trials
    17d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026
    Trial initiation date
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    27d
    SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients. (PubMed, Curr Oncol)
    Genomic classifier tools help identifying aggressiveness of cancers and aid in personalized treatment decision-making. Joint efforts of multidisciplinary physicians are crucial to improve health outcomes for patients with PCa across the spectrum of this disease.
    Review • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • CHEK2 (Checkpoint kinase 2) • EPCAM (Epithelial cell adhesion molecule) • HOXB13 (Homeobox B13)
    3ms
    Germline DNA Repair and Immune-metabolic Alterations Suggest a Potentially Distinct Form of Early-onset Prostate Cancer in Men of African Descent. (PubMed, Eur Urol Oncol)
    This study reveals a broader germline landscape in early-onset PCa among men of African descent. Inherited immune-metabolic dysfunction may contribute to tumorigenesis through microenvironmental dysregulation, highlighting novel pathways for investigation in larger and ancestrally diverse cohorts.
    Journal
    |
    TYRP1 (Tyrosinase Related Protein 1) • HOXB13 (Homeobox B13)
    3ms
    Emerging biomarkers in prostate cancer diagnosis and treatment: Insights into genetic, RNA and metabolic markers (Review). (PubMed, Int J Oncol)
    Moreover, integrating multi‑omics data with artificial intelligence and machine learning may further improve early detection and personalized treatment strategies. Overall, the development and clinical implementation of these biomarkers represent a transformative step toward precision medicine in prostate cancer, enabling earlier diagnosis, optimized therapy selection and improved patient outcomes.
    Review • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • GSTP1 (Glutathione S-transferase pi 1) • RASSF1 (Ras Association Domain Family Member 1) • HOXB13 (Homeobox B13) • PCA3 (Prostate cancer associated 3)
    3ms
    Distinct transcription factor interactions drive HOXB13 activity in different stages of prostate cancer. (PubMed, Proc Natl Acad Sci U S A)
    The HOXB13/SMARCD2 interaction alters chromatin accessibility at HOXB13-binding sites, causing increased proliferation in AR-negative PCa. Overall, this work demonstrates a distinct mechanism of action for HOXB13 and highlights its critical role in AR-negative castration-resistant PCa.
    Journal
    |
    HOXB13 (Homeobox B13)
    |
    AR positive
    3ms
    Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation. (PubMed, Virchows Arch)
    No ABC showed AR positivity, while this was observed in rare cells (IRS 1-2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.
    Journal
    |
    AR (Androgen receptor) • HOXB13 (Homeobox B13) • NKX3-1 (NK3 homeobox 1)
    |
    AR positive
    3ms
    Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Northwell Health | Trial completion date: Oct 2026 --> Oct 2028 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CHEK2 (Checkpoint kinase 2) • HOXB13 (Homeobox B13)
    3ms
    Targeting p300 and CBP abolishes HOXB13-loss-induced lipogenesis and tumor metastasis. (PubMed, JCI Insight)
    Analysis of clinical samples revealed that HOXB13 expression is reduced in metastatic hormone-sensitive PCa compared with matched primary tumors, further supporting its role in tumor metastasis. These findings demonstrate that HOXB13 downregulation promotes PCa metastasis through p300- and CBP-dependent lipogenic and motility pathways, which may be targeted by p300 inhibition.
    Journal
    |
    AR (Androgen receptor) • HDAC3 (Histone Deacetylase 3) • HOXB13 (Homeobox B13)
    3ms
    The Role of Genetic Testing in Localized Prostate Cancer. (PubMed, Urol Clin North Am)
    Consensus recommendations and guidelines now endorse routine germline testing in men with high-risk localized disease, strong family history, or known familial mutations. Germline information, as well as somatic genomic classifiers, is increasingly being used to help guide screening and treatment recommendations.
    Review • Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2) • HOXB13 (Homeobox B13)
    3ms
    Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry. (PubMed, Eur Urol)
    Integration of PV status, PRS, and family history enables more refined PCa risk estimates. The wide range of PCa risk observed among men of African ancestry in our study supports future prospective studies in the development of risk-stratified cancer screening programs to identify high-risk individuals who may benefit from screening at an earlier age.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • HOXB13 (Homeobox B13)
    4ms
    Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. (PubMed, Nat Genet)
    Mechanistically, we show PTGES3 binds directly to AR, regulates AR protein stability and is necessary for AR function in the nucleus at AR target genes. PTGES3 represents a potential therapeutic target for overcoming known mechanisms of resistance to existing AR-directed therapies in PCa.
    Journal
    |
    AR (Androgen receptor) • GATA2 (GATA Binding Protein 2) • HOXB13 (Homeobox B13) • PTGES (Prostaglandin E Synthase)
    4ms
    Prevalence and clinical significance of the rare HOXB13 X285K variant in a French Caribbean prostate cancer cohort. (PubMed, BMC Cancer)
    Although limited by small sample size, these findings suggest a possible link between the HOXB13 X285K variant and early tumor progression. This highlights the importance of screening for this rare variant, particularly in patients of African descent who are underrepresented in genomic studies, to support improved risk stratification and personalized management.
    Journal
    |
    HOXB13 (Homeobox B13)